TMPRSS2 and prostate carcinoma: We further examined the activity of type 3 AR variants in prostate cancer Du145 and PC3 cells and breast cancer MDA-MB-453 and MFM-223 cells but found no androgen-independent activation of the PSA or TMPRSS2 enhancer reporter in these cell contexts (data not shown).